Amphastar Pharmaceuticals, Inc.
AMPH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001297184
In the last 90 days, Amphastar Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 227 institutions reported holding it in 13F filings for Q3 2026, worth $754.6M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:44 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 28, 2024 | Feb 28, 2023 | Mar 10, 2022 |
| Revenue | $719.9M | $732.0M | $644.4M | $499.0M | $437.8M |
| Cost of revenue | $363.8M | $358.1M | $293.3M | $250.1M | $238.0M |
| Gross profit | $356.1M | $373.9M | $351.1M | $248.9M | $199.7M |
| Operating expenses | $215.7M | $168.4M | $154.1M | $141.4M | $129.9M |
| Research and development | $85.8M | $73.9M | $73.7M | $74.8M | $60.9M |
| Selling, general and administrative | $85.9M | $56.7M | $51.5M | $45.1M | $51.4M |
| Operating income | $140.4M | $205.4M | $197.0M | $107.5M | $69.9M |
| Interest expense | – | – | $27.2M | $1.85M | $885.0K |
| Income tax | $25.5M | $29.7M | $31.8M | $23.5M | $20.6M |
| Net income | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M |
| EPS, basic | $2.10 | $3.29 | $2.85 | $1.88 | $1.30 |
| EPS, diluted | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 |
| Weighted shares, basic | 46.7M | 48.4M | 48.3M | 48.6M | 47.8M |
| Weighted shares, diluted | 48.2M | 52.1M | 53.0M | 52.4M | 49.8M |
| Margins and growth | |||||
| Gross margin | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% |
| Operating margin | 19.5% | 28.1% | 30.6% | 21.5% | 16.0% |
| Net margin | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% |
| Revenue growth, year over year | −1.7% | +13.6% | +29.1% | +14.0% | +25.1% |
| Net income growth, year over year | −38.5% | +16.0% | +50.5% | +47.1% | +4,327.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 28, 2024 | Feb 28, 2023 | Mar 10, 2022 |
| Cash and equivalents | $170.2M | $151.6M | $144.3M | $156.1M | $126.4M |
| Short-term investments | $112.6M | $70.0M | $112.5M | $19.7M | $10.3M |
| Accounts receivable | $143.6M | $136.3M | $114.9M | $88.8M | $78.8M |
| Inventory | $176.9M | $153.7M | $105.8M | $103.6M | $92.8M |
| Total current assets | $636.0M | $534.1M | $489.6M | $378.3M | $318.1M |
| Property, plant and equipment | $310.6M | $297.3M | $282.7M | $238.3M | $244.2M |
| Goodwill | $3.40M | $3.05M | $3.22M | $3.13M | $3.31M |
| Intangible assets | $533.3M | $558.4M | $580.9M | $4.95M | $6.33M |
| Total assets | $1.63B | $1.58B | $1.51B | $742.0M | $671.5M |
| Accounts payable | $32.6M | $30.5M | $25.4M | $20.5M | $22.2M |
| Total current liabilities | $158.2M | $173.8M | $225.4M | $94.9M | $103.8M |
| Long-term debt | $619.7M | $613.5M | $603.2M | $76.6M | $78.2M |
| Total liabilities | $840.5M | $845.2M | $873.5M | $213.3M | $226.0M |
| Shareholders' equity | $788.8M | $732.3M | $639.4M | $528.7M | $445.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 28, 2024 | Feb 28, 2023 | Mar 10, 2022 |
| Operating cash flow | $156.1M | $213.4M | $183.5M | $89.2M | $98.0M |
| Capital expenditures | $34.9M | $41.0M | $38.2M | $24.0M | $27.5M |
| Free cash flow | $121.2M | $172.3M | $145.3M | $65.1M | $70.5M |
| Depreciation and amortization | – | – | $25.7M | $12.6M | $10.2M |
| Stock-based compensation | $27.3M | $24.4M | $20.2M | $17.9M | $18.7M |
| Share buybacks | $75.6M | $85.5M | $58.1M | $39.9M | $28.9M |
| Investing cash flow | -$70.3M | -$124.9M | -$649.1M | -$32.8M | -$28.7M |
| Financing cash flow | -$67.4M | -$81.0M | $454.1M | -$26.4M | -$37.0M |
| Net change in cash | $18.6M | $7.31M | -$11.8M | $29.7M | $32.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 3.8% | 3.3% | 3.1% | 3.6% | 4.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 42.7M | −7.2% | SEC |
| Jul 31, 2026 | 42.5M | −8.5% | SEC |
| May 1, 2026 | 44.1M | −6.5% | SEC |
| Feb 20, 2026 | 45.4M | −4.8% | SEC |
| Oct 31, 2025 | 46.0M | −4.4% | SEC |
| Aug 1, 2025 | 46.5M | −4.5% | SEC |
| May 1, 2025 | 47.1M | −3.6% | SEC |
| Feb 25, 2025 | 47.7M | −0.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.